Sugi Predict

Sugi Predict / Compounds / SCHEMBL3106472

SCHEMBL3106472

SCHEMBL3106472

CCNC(=O)c1ccc(N)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HTT P42858 1/20 0.45
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ ADRB2 P07550 1/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ ADRB3 P13945 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ LMNA P02545 3/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ PDE10A Q9Y233 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SLC22A2 O15244 1/20 0.40
▸ SLC22A1 O15245 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126727 0.87 POLB (0.53) CRBNSMN1; SMN2HTTCYP1A2CYP2C19
SCHEMBL7233950 0.86 SMN1; SMN2 (0.43) SMN1; SMN2CYP1A2CYP2C19MAPTCYP2C9
SCHEMBL11120428 0.84 LMNA (0.43) MAPTALDH1A1LMNAGAAMAPK1
SCHEMBL27452028 0.84 HTT (0.57) SMN1; SMN2HTTALDH1A1LMNANPC1
SCHEMBL10528953 0.83 KDM4E (0.60) CRBNSMN1; SMN2HTTCYP1A2CYP2C19
SCHEMBL4156165 0.82 SMN1; SMN2 (0.64) SMN1; SMN2HTTMAPTALDH1A1LMNA
SCHEMBL3107614 0.81 POLB (0.54) CRBNSMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL3117436 0.81 CRBN (0.45) CRBNLMNAGAAHTR2AHDAC3
SCHEMBL11785384 0.81 HTR2A (0.41) HTTCYP2C19MAPTCYP2C9ALDH1A1
SCHEMBL11785377 0.81 HTR2A (0.41) HTTCYP2C19MAPTCYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240308984-A1 Jak Inhibitor With High Oral Bioavailability TECHNODERMA MEDICINES INC (CN) 2024-09-19 — — US disclosed
EP-4382522-A1 JAK INHIBITOR WITH HIGH ORAL BIOAVAILABILITY Technoderma Medicines Inc. (CN) 2024-06-12 — — EP disclosed
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF TECHNODERMA MEDICINES INC (CN) 2023-11-23 — — US disclosed
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF TECHNODERMA MEDICINES INC (CN) 2023-11-23 — — US disclosed
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF TECHNODERMA MEDICINES INC (CN) 2023-11-23 — — US disclosed
EP-4227298-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF Technoderma Medicines Inc. (CN) 2023-08-16 — — EP disclosed
WO-2023011301-A1 JAK INHIBITOR WITH HIGH ORAL BIOAVAILABILITY 嘉兴特科罗生物科技有限公司 2023-02-09 — — WO disclosed
WO-2023011301-A1 JAK INHIBITOR WITH HIGH ORAL BIOAVAILABILITY 嘉兴特科罗生物科技有限公司 2023-02-09 — — WO disclosed
CN-113603677-B JAK inhibitor with high oral bioavailability 嘉兴特科罗生物科技有限公司 2022-06-14 — — CN disclosed
WO-2022073424-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF 嘉兴特科罗生物科技有限公司 2022-04-14 — — WO disclosed
EP-3183247-B1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS PFIZER (US) 2017-11-29 — — EP disclosed
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2017-08-24 — — US disclosed
CN-107074867-A Aminopyrimidinyl compounds as JAK inhibitors 辉瑞公司 2017-08-18 — — CN disclosed
EP-3183247-A1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS Pfizer Inc (US) 2017-06-28 — — EP disclosed
US-9663526-B2 Aminopyrimidinyl compounds PFIZER INC. (US) 2017-05-30 — — US disclosed
WO-2016027195-A1 AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS PFIZER INC. (US) 2016-02-25 — — WO disclosed
US-20160052930-A1 AMINOPYRIMIDINYL COMPOUNDS PFIZER INC. (US) 2016-02-25 — — US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373933-A1 SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR AND USE THEREOF JAK1, TYK2, JAK2 CRBN 506/4885SMN1; SMN2 4419/4885HTT 2472/4885
US-20170239264-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 CRBN 26/4885SMN1; SMN2 2668/4885HTT 480/4885
US-20160052930-A1 AMINOPYRIMIDINYL COMPOUNDS CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 CRBN 26/4885SMN1; SMN2 2668/4885HTT 480/4885
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 CRBN 2192/4885SMN1; SMN2 4399/4885HTT 969/4885
US-20240308984-A1 Jak Inhibitor With High Oral Bioavailability JAK1, JAK2, JAK3 CRBN 1993/4885SMN1; SMN2 3963/4885HTT 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback